Reinventing HCV Treatment: Past and Future Perspectives

Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2017, Pages 287-296

  Carter, Wendy ^a   Connelly, Sarah ^a   Struble, Kimberly ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

direct acting antivirals; genotype; hepatitis C; resistance associated variants; sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; NONSTRUCTURAL PHOSPHOPROTEIN 5A, GB VIRUS TYPE C; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3-4A SERINE PROTEASE, HEPATITIS C VIRUS; PHOSPHOPROTEIN; PROTEINASE INHIBITOR; RIBAVIRIN; SERINE PROTEINASE; VIRAL PROTEIN;

ANTIVIRAL THERAPY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HISTORY; HUMAN; LIVER CIRRHOSIS; NONHUMAN; REVIEW; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIROLOGY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; PHOSPHOPROTEINS; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; SERINE PROTEASES; SUSTAINED VIROLOGIC RESPONSE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84996549884     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.830     Document Type: Review

References (69)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359–362.
2. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327.
3. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84(11):1744–1750.
4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 suppl):S45–S57.
5. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
6. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol. 2015;53(3):967–972.
7. Simmonds P. Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol. 2004;85(11):3173–3188.
8. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014;61(1 suppl):S34–S44.
9. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014–1018.
10. Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology. 2009;137(3):795–814.
11. CDC. Travelers' Health. Chapter 3: Infectious diseases related to travel hepatitis C. 2015. http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-c. Accessed May 11, 2016.
12. Gish RG, Cohen CA, Block JM, et al. Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology. 2015;62(5):1339–1341.
13. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353–1363.
14. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–278.
15. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287–1288.
16. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.
17. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–521, 521e1–6.
18. Bukh J. Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology. 2012;142(6):1279–1287.e3.
19. Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol. 2014;61(1 suppl):S3–S13.
20. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012;61 (1 suppl):i25–i35.
21. Schiffer JT, Scott J, Corey L. A siege of hepatitis: fighting a defiant virus. Nat Med. 2011;17(3):253–254.
22. Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of hepatitis C virus to inhibitors: complexity and clinical implications. Viruses. 2015;7(11):5746–5766.
23. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62(5):1623–1632.
24. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280–288, 8e1.
25. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–516,e1.
26. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–2593.
27. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term Tteatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730–740.
28. FDA Draft Guidance for Industry. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment. May 2016. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm225333.pdf
29. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–1455, e2.
30. Intron®[package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011. https://www.merck.com/product/usa/pi_circulars/i/intron_a/intron_a_pi.pdf. Accessed May 11, 2016.
31. Ribasphere® [package insert]. Warrendale, PA: Kadmon Pharmaceuticals, LLC; 2015. http://kadmon.com/files/ribasphere-tablets-pi.pdf. Accessed May 11, 2016.
32. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
33. Pegasys [package insert]. South San Francisco, CA: Genentech, Inc.; 2015. http://www.gene.com/download/pdf/pegasys_prescribing.pdf. Accessed May 11, 2016.
34. Pegintron®[package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2013. https://www.merck.com/product/usa/pi_circulars/p/pegintron/pegintron_pi.pdf. Accessed May 11, 2016.
35. Incivek® [package insert]. Cambridge, MA: Vertex Pharmaceuticals, Inc.; 2013. http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed May 11, 2016.
36. Victrelis [package insert]. Schering Corporation, a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ: Schering Corporation; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf. Accessed May 11, 2016.
37. Sovaldi® [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2015. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Accessed May 11, 2016.
38. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205123s010lbl.pdf. Accessed May 11, 2016.
39. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2016. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed June 16, 2016.
40. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; 2016. http://www.rxabbvie.com/pdf/viekirapak_pi.pdf. Accessed June 16, 2016.
41. Zepatier [package insert]. Whitehouse Station, NJ: Merch & Co., Inc.; 2016. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf. Accessed May 11, 2016.
42. Daklinza[package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016. http://packageinserts.bms.com/pi/pi_daklinza.pdf. Accessed May 11, 2016.
43. Epclusa®[package insert]. Foster City, CA: Gilead Sciences, Inc.; 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf. Accessed June 28, 2016.
44. Technivie [package insert]. North Chicago, IL: AbbVie Inc.; 2016. http://www.rxabbvie.com/pdf/technivie_pi.pdf. Accessed June 16, 2016.
45. Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2016. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed June 16, 2016.
46. Copegus [package insert]. South San Francisco, CA: Genetech, Inc.; 2015. http://www.gene.com/download/pdf/copegus_prescribing.pdf. Accessed May 11, 2016.
47. Rebetol [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2013. https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf. Accessed May 11, 2016.
48. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med. 1998;339(21):1493–1499.
49. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339(21):1485–1492.
50. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351(9096):83–87.
51. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426–1432.
52. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20(18):2361–2369.
53. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20(1):49–57.
54. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7(1):261–287.
55. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol. 2015;7(12):1617–1631.
56. Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63(6):1511–1522.
57. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282(5386):103–107.
58. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64–71.
59. Horner SM, Naggie S. Successes and challenges on the road to cure hepatitis C. PLoS Pathogens. 2015;11(6):e1004854.
60. US Food and Drug Administration, Center for Drug Evaluation and Research. Zepatier NDA 208261 Medical Division Director Summary Review, January, 28, 2016. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000SumR.pdf. Accessed June 16, 2016.
61. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.
62. Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59(9):5445–5454.
63. Sulkowski M, Krishnan P, Tripathi R, et al. Effect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV. Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston, MA.
64. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151(3):501–512.
65. Kwo M, Bennett M, Wang S, et al. SURVEYOR-II: high SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naïve and treatment-experienced patients with HCV genotype 3 infection. The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 13-17, 2015; San Francisco.
66. Wyles D, Sulkowski M, Wang W, et al. SURVEYOR-II: High SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naïve and treatment-experienced patients with HCV genotype 2 infection. The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 13-17, 2015; San Francisco.
67. Poordad F, Felizarta F, Asatryan A, et al. SURVEYOR-I: 98%–100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or pegylated interferon/ribavirin null-responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530. The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 13-17, 2015; San Francisco.
68. TM EASL—European Association for the Study of the Liver; Barcelona, Spain; 2016.
69. Lawitz E, Kowdley K, Curry M, et al. High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1-6 HCV-infected patients, including those previously treated with direct-acting antivirals: The International Liver Congress™ EASL—European Association for the Study of the Liver; Barcelona, Spain; 2016.